Cell · 2017
Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aggarwal Anup, Parai Maloy K, Shetty Nishant, Wallis Deeann, Woolhiser Lisa, Hastings Courtney, Dutta Noton K, Galaviz Stacy, Dhakal Ramesh C, Shrestha Rupesh, Wakabayashi Shoko, Walpole Chris, Matthews David, Floyd David, Scullion Paul, Riley Jennifer, Epemolu Ola, Norval Suzanne, Snavely Thomas, Robertson Gregory T, Rubin Eric J, Ioerger Thomas R, Sirgel Frik A, van der Merwe Ruben, van Helden Paul D, Keller Peter, Böttger Erik C, Karakousis Petros C, Lenaerts Anne J, Sacchettini James C
Аннотация
Widespread resistance to first-line TB drugs is a major problem that will likely only be resolved through the development of new drugs with novel mechanisms of action. We have used structure-guided methods to develop a lead molecule that targets the thioesterase activity of polyketide synthase Pks13, an essential enzyme that forms mycolic acids, required for the cell wall of Mycobacterium tuberculosis. Our lead, TAM16, is a benzofuran class inhibitor of Pks13 with highly potent in vitro bactericidal activity against drug-susceptible and drug-resistant clinical isolates of M. tuberculosis. In multiple mouse models of TB infection, TAM16 showed in vivo efficacy equal to the first-line TB drug isoniazid, both as a monotherapy and in combination therapy with rifampicin. TAM16 has excellent pharmacological and safety profiles, and the frequency of resistance for TAM16 is ∼100-fold lower than INH, suggesting that it can be developed as a new antitubercular aimed at the acute infection. PAPERCLIP.